Takeda Pharmaceutical Co. $TAK Stock Holdings Increased by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC increased its holdings in Takeda Pharmaceutical Co. (NYSE:TAK) by 26.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 13,758 shares of the company’s stock after purchasing an additional 2,878 shares during the quarter. Sagespring Wealth Partners LLC’s holdings in Takeda Pharmaceutical were worth $213,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Goldman Sachs Group Inc. raised its holdings in shares of Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after purchasing an additional 692,404 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new stake in shares of Takeda Pharmaceutical in the 1st quarter worth approximately $51,049,000. Federated Hermes Inc. raised its holdings in shares of Takeda Pharmaceutical by 24.6% in the 1st quarter. Federated Hermes Inc. now owns 541,919 shares of the company’s stock worth $8,058,000 after purchasing an additional 106,885 shares in the last quarter. Royal Bank of Canada raised its holdings in shares of Takeda Pharmaceutical by 11.0% in the 1st quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock worth $6,558,000 after purchasing an additional 43,706 shares in the last quarter. Finally, QRG Capital Management Inc. raised its holdings in shares of Takeda Pharmaceutical by 11.8% in the 2nd quarter. QRG Capital Management Inc. now owns 432,654 shares of the company’s stock worth $6,689,000 after purchasing an additional 45,726 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently commented on TAK shares. Zacks Research downgraded shares of Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a report on Thursday, August 21st. Weiss Ratings reissued a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research report on Tuesday, October 14th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical currently has a consensus rating of “Hold”.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $14.05 on Friday. The company’s 50 day moving average price is $14.81 and its 200 day moving average price is $14.75. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.69. The company has a market capitalization of $44.71 billion, a PE ratio of 46.83 and a beta of 0.21. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. Research analysts expect that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.